|

Comprehensive Assessment of Cancer Theranostic Response

RECRUITINGN/ASponsored by AIQ Solutions
Actively Recruiting
PhaseN/A
SponsorAIQ Solutions
Started2024-12-02
Est. completion2026-03-30
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →

NCT06815354

Summary

The intent of this study is to evaluate actionable outputs from TRAQinform Theranostics in a prospective, multi-center, non-interventional clinical study. The primary objective is to investigate intent-to-change treatment decisions after the addition of TRAQinform Theranostics. The exploratory objective is to investigate if treatment efficacy and treatment-related toxicity could be detected by TRAQinform Theranostics following PSMA PET/CT at week 12.

Eligibility

Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Age 18 years or older and willing and able to provide informed consent.
* Diagnosis of metastatic prostate cancer.
* Planned to start 177Lu-PSMA (Pluvicto).
* Ability to tolerate two 68Ga-PSMA or 18F-DCFPyL PET/CT imaging procedures. One at baseline and at 12 weeks of 177Lu-PSMA (Pluvicto) treatment.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 at screening.

Exclusion Criteria:

* Any concurrent disease, infection, or comorbid condition that interferes with the ability of the patient to participate in the trial.

Conditions2

CancerProstate Cancer

Locations2 sites

New York

1 site
Weill Medical College of Cornell
New York, New York, 10065
GU Oncology Program646-962-2072guonc@med.cornell.edu

Texas

1 site
M.D. Anderson Cancer Center
Houston, Texas, 77030
Paul Corn, MD713-563-7208pcorn@mdanderson.org

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.